On December 30, 2025, Insilico Medicine began trading on the Main Board of the Hong Kong Stock Exchange under ticker 3696.HK. The generative-AI drug discovery company offered 94,690,500 shares globally and raised HK$2.277 billion — the largest biotech IPO in Hong Kong that year by fundraising size, and the first AI-driven biotech to list on the city’s Main Board under the Chapter 8.05 rules. Morgan Stanley, CICC, and GF Securities sponsored the deal.
Why it matters: AI drug discovery has been discussed for a decade, with plenty of narrative and very little priced public-market validation. On debut day, Insilico’s Hong Kong public offering was oversubscribed roughly 1,427.37 times, locking in over HK$328.349 billion in subscription funds, while the international tranche was covered 26.27 times over. For the first time at this scale, the secondary market put real demand behind the question “can AI actually produce drugs?”
The Debut: 1,427x Oversubscription
The book structure rewards a closer look. The retail tranche was only 10% of the global offering, yet it drew more than HK$328 billion — a record among Hong Kong’s non-18A healthcare IPOs that year. The 26.27x coverage on the international placement was likewise the year’s highest in the non-18A healthcare category.
The cornerstone list ran fifteen names deep: Lilly, Tencent, Temasek, Schroders, UBS Asset Management, Oaktree, E Fund, and Taikang Life Insurance among them. Lilly and Tencent were both first-time biotech cornerstone investors, and Oaktree returned to Hong Kong biotech for the first time this year. Big pharma, tech capital, and traditional institutional money in the same syndicate is itself a vote on the category.
Rentosertib: An 18-Month, 78-Molecule Proof
What the market was buying is the pipeline, and Insilico’s flagship evidence is rentosertib (ISM001-055), a first-in-class candidate for idiopathic pulmonary fibrosis (IPF). The program went from discovery to a preclinical candidate (PCC) in 18 months, testing only 78 molecules along the way. Compare that with the traditional benchmark of roughly 4.5 years and 60 to 200 molecules tested per program: that gap is the product.
On the clinical side, the China Phase IIa completed in 2024, and results published in Nature Medicine in May 2025 showed favorable safety with a dose-dependent efficacy trend — which the company frames as the first clinical proof-of-concept milestone for AI drug discovery, building on discovery-phase work published in Nature Biotechnology in March 2024. The broader portfolio counts more than 30 programs, 10 IND clearances, and 7 assets in active clinical development across fibrosis, oncology, immunology, cardiometabolic disease, and CNS.
Why Hong Kong
Choosing HKEX over Nasdaq is more about the path than the geography. Hong Kong biotech IPOs have spent the past decade flowing through Chapter 18A, the unprofitable-biotech route; Insilico listed under the standard Chapter 8.05 rules, which means a conventional financial test absorbed an “AI platform plus pipeline” story. The city’s largest biotech raise of the year landing on an AI company, with 1,427x retail demand attached, sends a direct signal to Asia-Pacific private markets: AI-biotech companies now have an explicit exit path and a pricing reference point.
Use of Proceeds and the Industry Signal
Of the net proceeds, roughly 48% funds clinical development of key pipeline candidates, 20% goes to early-stage discovery, 15% to developing and validating new generative AI models, 12% to expanding the automated laboratories (Life Star 1 went live in December 2022, Life Star 2 in September 2025), and 5% to working capital. That 15% figure deserves a pause: a listed biotech earmarking model development as a primary use of proceeds treats AI capability as a core asset, not a one-off tool.
There is already commercial revenue shape to point at: three out-licensing deals (including Exelixis and Menarini) with total value up to $2.1 billion, co-development work with Fosun Pharma, Sanofi, and Lilly, and software licenses held by 13 of the world’s top 20 pharma companies. Founder and CEO Alex Zhavoronkov frames the mission as extending human “productive longevity,” while Co-CEO and CSO Feng Ren argues the value of AI runs “far beyond cost reduction and efficiency gains.” For developers and product teams, the takeaway is simple: once the full stack — generative models, automated labs, clinical validation — gets a public market price, the acceptance bar for AI in science moves from papers to revenue and pipeline progress.
Sources
- Insilico Medicine Lists on Hong Kong Stock Exchange — Insilico Medicine
- Insilico Medicine Lists on HKEX, 2025’s Largest Hong Kong Biotech IPO — PR Newswire
AI-assisted summary compiled from the sources above, reviewed by a human before publishing.